Short answer
Insmed Incorporated (INSM) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $524M (up 268.4% year over year) with net income of −$100M.
Q3 2026 key financials · XBRL
- Revenue
- $524M
- +268.4% YoY · +23.3% QoQ
- Net income
- −$100M
- +72.9% YoY · −657.6% QoQ
- Operating margin
- -17.0%
- EPS (diluted)
- −$0.46
- +74.0% YoY · −666.7% QoQ
Source: XBRL data from the Insmed Incorporated (INSM) Q3 2026 10-Q on SEC EDGAR. USD.
Insmed Incorporated Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $524.4M, up $382.1M or 268% YoY, driven by BRINSUPRI
- BRINSUPRI revenue $400.1M vs $28.1M, while ARIKAYCE revenue rose 9% to $124.4M
- Cost margin 85.1% vs 79.4% YoY, based on product costs of 14.9% vs 20.6% of revenue
- Cash and securities $1.15B vs $1.43B at December 31, 2025, with $348.0M operating cash use
- Outlook: funding expected for at least 12 months, with BRINSUPRI commercialization and TPIP development driving cash needs
Risk Factors
- No material risk-factor changes identified versus the December 31, 2025 Form 10-K
- Carried-forward business risk: risks could materially affect financial condition, operations, growth prospects, and common-stock value
- Carried-forward disclosure risk: actual results may differ materially from forward-looking statements
- Filing provides no new regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insmed Incorporated quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.